Impact of Chronic Exposure to Radiofrequency Electromagnetic Fields on Neurophysiological Development in the Preterm Neonate (NeuroPrem-RF)

The massive use of highly technological devices in Neonatal Intensive Care Units may expose preterm neonates to electromagnetic fields, especially radiofrequencies, at low doses but continuously and chronically. Strikingly, the effect of long-term exposure to radiofrequencies on the neurophysiological development of preterm neonates has never been studied so far. The only studies on the impact of chronic exposure to radiofrequencies have been conducted in animals or adult humans, whereas preterm infants may be particularly vulnerable due to increased penetration of radiofrequency waves into the brain during a crucial period of neurodevelopment. The present project will aim at 1) quantifying individual levels of chronic exposure (during 6 weeks) to which preterm neonates are subjected during their stay in the Neonatal Intensive Care Unit, 2) following the evolution of the thermal environment and of the clinical parameters of the neonates after birth, 3) identifying potential alterations of neurophysiological activity (sleep, cerebral hemodynamics, autonomic nervous activity) which will be correlated to actual levels of chronic RF-EMF (radiofrequency electromagnetic fields) exposure.

Study Overview

Detailed Description

Preterm infants are potentially exposed to chronic, low levels of electromagnetic fields, especially radiofrequencies, while hospitalized in neonatal intensive care units. Moreover, they may be particularly vulnerable due to increased penetration of radiofrequency waves into the brain during a crucial period of neurodevelopment. This study will aim at evaluating the influence of radiofrequency electromagnetic fields exposure on the neurophysiological development in preterm neonates.

The first part of this study will be devoted to the measurement of environmental electromagnetic fields in order to map their distribution in the paediatric department. From birth and during 6 weeks, the investigators will perform, for each child, a continuous measurement of radiofrequencies at the incubator level. Infants' clinical data (medical history, nutrition, morphology...) and the evolution of the thermal environment in incubators (air and body temperatures) will also be continually monitored. At 3 and 6 weeks of life, the investigators will investigate sleep (EEG, EOG), cerebral hemodynamics (near-infrared spectroscopy), autonomic nervous system activity (ECG, heart rate variability) and various cardiorespiratory parameters (SpO2, apnoea, bradycardia) thanks to a night-time polysomnography.

The impact of radiofrequency electromagnetic fields will be evaluated by analyses of the relationship between exposure levels and the various parameters extracted from the neurophysiological investigation phase.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Amiens, France, 80054
        • CHU Amiens

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 1 day (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • preterm neonates born at 26 to 34 weeks of gestational age
  • signed written informed consent form

Exclusion Criteria:

  • infants infected
  • infants suffering from neurological disorders
  • serious heart, respiratory, digestive or metabolic diseases
  • infants born from mothers aged less than 18 years old or deprived of their parental rights
  • non covered by national health insurance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: preterm neonate
Parental questionnaire on pregnancy history and environmental exposure
Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator
Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures…)
Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),
cerebral hemodynamics (near infrared spectroscopy)
activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
total sleep time in hours
Time Frame: from birth to 6 weeks of life
Sleep Structure will be determined by measuring total sleep time, absolute and relative durations of sleep states and sleep state change frequency.
from birth to 6 weeks of life
absolute durations of sleep states in hours
Time Frame: from birth to 6 weeks of life
Sleep Structure will be determined by measuring total sleep time, absolute and relative durations of sleep states and sleep state change frequency.
from birth to 6 weeks of life
relative durations of sleep states in hours
Time Frame: from birth to 6 weeks of life
Sleep Structure will be determined by measuring total sleep time, absolute and relative durations of sleep states and sleep state change frequency.
from birth to 6 weeks of life
sleep state change frequency
Time Frame: from birth to 6 weeks of life
Sleep Structure will be determined by measuring total sleep time, absolute and relative durations of sleep states and sleep state change frequency.
from birth to 6 weeks of life

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cerebral hemodynamics
Time Frame: from birth to 6 weeks of life
Cerebral hemodynamics will be determined by measuring regional cerebral oxygen saturation
from birth to 6 weeks of life
Autonomic nervous system activity
Time Frame: from birth to 6 weeks of life
Autonomic nervous system activity will be determined by measuring means of a heart rate variability
from birth to 6 weeks of life
apnea frequency
Time Frame: from birth to 6 weeks of life
cardiorespiratory parameters (apnea, bradycardia, desaturation) will be determined
from birth to 6 weeks of life
bradycardia frequency
Time Frame: from birth to 6 weeks of life
cardiorespiratory parameters (apnea, bradycardia, desaturation) will be determined
from birth to 6 weeks of life
desaturation frequency
Time Frame: from birth to 6 weeks of life
cardiorespiratory parameters (apnea, bradycardia, desaturation) will be determined
from birth to 6 weeks of life
Evolution of the anthropomorphic characteristics of the subjects
Time Frame: from birth to 6 weeks of life
anthropomorphic characteristics of the subjects are height and weight. Weight and height will be combined to report BMI in kg/m^2.
from birth to 6 weeks of life

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pierre Tourneux, Pr, CHU Amiens
  • Principal Investigator: François Moreau, MD, CHU Amiens
  • Principal Investigator: Lucie Aimée Razafimanantsoa, MD, CHU Amiens

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

May 1, 2023

Study Completion (Anticipated)

August 1, 2023

Study Registration Dates

First Submitted

April 16, 2019

First Submitted That Met QC Criteria

April 23, 2019

First Posted (Actual)

April 26, 2019

Study Record Updates

Last Update Posted (Actual)

May 10, 2023

Last Update Submitted That Met QC Criteria

May 9, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Infant

Clinical Trials on Parental questionnaire

3
Subscribe